EchitamineCAS# 6871-44-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 6871-44-9 | SDF | Download SDF |
| PubChem ID | 11953926 | Appearance | Powder |
| Formula | C22H29N2O4 | M.Wt | 385.5 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CC=C1C[N+]2(CCC34C2(C(CC1C3(CO)C(=O)OC)O)NC5=CC=CC=C45)C | ||
| Standard InChIKey | AFJPGVUCVDCFPM-OBYWIAIFSA-N | ||
| Standard InChI | InChI=1S/C22H29N2O4/c1-4-14-12-24(2)10-9-21-15-7-5-6-8-17(15)23-22(21,24)18(26)11-16(14)20(21,13-25)19(27)28-3/h4-8,16,18,23,25-26H,9-13H2,1-3H3/q+1/b14-4-/t16-,18-,20?,21-,22-,24-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Echitamine chloride possesses anti-tumour activity in-vitro and in-vivo. |
Echitamine Dilution Calculator
Echitamine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.594 mL | 12.9702 mL | 25.9403 mL | 51.8807 mL | 64.8508 mL |
| 5 mM | 0.5188 mL | 2.594 mL | 5.1881 mL | 10.3761 mL | 12.9702 mL |
| 10 mM | 0.2594 mL | 1.297 mL | 2.594 mL | 5.1881 mL | 6.4851 mL |
| 50 mM | 0.0519 mL | 0.2594 mL | 0.5188 mL | 1.0376 mL | 1.297 mL |
| 100 mM | 0.0259 mL | 0.1297 mL | 0.2594 mL | 0.5188 mL | 0.6485 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Asimilobine
Catalog No.:BCN7076
CAS No.:6871-21-2
- 13,18-Dehydroglaucarubinone
Catalog No.:BCN7957
CAS No.:68703-94-6
- 11β,17α-Dihydroxy-6α-methylpregna-1,4-diene-3,20-dione
Catalog No.:BCC8434
CAS No.:6870-94-6
- Jacobine
Catalog No.:BCN2087
CAS No.:6870-67-3
- Retronecine N-oxide
Catalog No.:BCN2035
CAS No.:6870-33-3
- Qianhucoumarin G
Catalog No.:BCN3704
CAS No.:68692-61-5
- IWP 4
Catalog No.:BCC5602
CAS No.:686772-17-8
- BC 11-38
Catalog No.:BCC7940
CAS No.:686770-80-9
- IWP-2
Catalog No.:BCC1665
CAS No.:686770-61-6
- (±)-Palmitoylcarnitine chloride
Catalog No.:BCC6718
CAS No.:6865-14-1
- BOP-Cl
Catalog No.:BCC2808
CAS No.:68641-49-6
- CP-945598 HCl
Catalog No.:BCC1082
CAS No.:686347-12-6
- (-)-Lotusine
Catalog No.:BCN8443
CAS No.:6871-67-6
- Arteanoflavone
Catalog No.:BCN6824
CAS No.:68710-17-8
- Xanthoplanine
Catalog No.:BCN4246
CAS No.:6872-88-4
- Epiberberine
Catalog No.:BCN5387
CAS No.:6873-09-2
- Phellodendrine
Catalog No.:BCN5933
CAS No.:6873-13-8
- Arborine
Catalog No.:BCN7480
CAS No.:6873-15-0
- Vellosimine
Catalog No.:BCN4758
CAS No.:6874-98-2
- (±)-Pinocembrin
Catalog No.:BCN3537
CAS No.:68745-38-0
- Loxoprofen
Catalog No.:BCC5191
CAS No.:68767-14-6
- Corynoxine
Catalog No.:BCN2364
CAS No.:6877-32-3
- 12-Hydroxy-2,3-dihydroeuparin
Catalog No.:BCN8115
CAS No.:68776-42-1
- 1beta-Hydroxyalantolactone
Catalog No.:BCN3508
CAS No.:68776-47-6
Evaluation of the cytotoxic effect of the monoterpene indole alkaloid echitamine in-vitro and in tumour-bearing mice.[Pubmed:16105243]
J Pharm Pharmacol. 2005 Sep;57(9):1213-9.
The cytotoxic effect of various concentrations of Echitamine chloride was studied in HeLa, HepG2, HL60, KB and MCF-7 cell lines in-vitro and in mice bearing Ehrlich ascites carcinoma (EAC). Exposure of various cells to different concentrations of Echitamine chloride resulted in a concentration-dependent cell killing, and KB cells were found to be most sensitive amongst all the cells evaluated. EAC mice treated with 1, 2, 4, 6, 8, 12 or 16 mg kg-1 Echitamine chloride showed a dose-dependent elevation in the anti-tumour activity, as evident by increased number of survivors in comparison with the non-drug treated controls. The highest dose of Echitamine chloride (16 mg kg-1) caused toxicity in the recipient mice, therefore 12 mg kg-1 was considered the best cytotoxic dose for its anti-tumour effect. Administration of 12 mg kg-1 Echitamine chloride resulted in an increase in the median survival time (MST) up to 30.5 days, which was 11.5 days higher than the non-drug treated control (19 days). Administration of 16 mg kg-1 Echitamine chloride to EAC mice resulted in a time dependent elevation in lipid peroxidation that reached a peak at 6 h post-treatment, whereas glutathione concentration declined in a time dependent manner and a maximum decline was reported at 3 h post-treatment. Our study demonstrated that Echitamine chloride possessed anti-tumour activity in-vitro and in-vivo.
